Comparative Cost-Efficacy Analysis of Darunavir/ritonavir and Other Ritonavir-Boosted Protease Inhibitors for First-Line Treatment of HIV-1 Infection in the United States

REFERENCES

• Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293–299.
   PubMed Web of Science ®Google Scholar
• Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA. 1993;270:474–478.
   PubMed Web of Science ®Google Scholar
• Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum RetroviroL 1997;16:54–62.
   PubMedGoogle Scholar
• Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990–997.
   PubMed Web of Science ®Google Scholar
• Yamashita TE, Phair JP, Munoz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS. 2001;15: 735–746.
   PubMed Web of Science ®Google Scholar
• Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13:1873–1880.
   PubMed Web of Science ®Google Scholar
• Gross R, Yip B, Lo Re V 3rd, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts fail-ure to maintain HIV-1 suppression. J Infect Dis. 2006;194: 1108–1114.
   PubMed Web of Science ®Google Scholar
• Legorreta A, Yu A, Chernicoff H, et al. Adherence to com-bined lamivudine + zidovudine versus individual compo-nents: a community-based retrospective medicaid claims analysis. AIDS Care. 2005;17:938–948.
   PubMed Web of Science ®Google Scholar
• Maitland D, Jackson A, Osorio J, et al. Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy. HIV Med. 2008;9:667–672.
   PubMed Web of Science ®Google Scholar
• Rosenblum M, Deeks SG, van der Laan M, et al. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretrovi-ral therapy. PLoS One. 2009;4:e7196.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555–570.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adoles-cents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. December 1, 2009. Avail-able at: http://AIDSinfo.nih.gov/Guidelines. Accessed December 3, 2009.
   Google Scholar
• Smith K, Fine D, Patel P, et al. Efficacy and safety of aba-cavir/lamivudine compared to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT study. Presented at: the 15th Confer-ence on Retroviruses and Opportunistic Infections (CR01); February 2008; Boston, MA, USA. Abstract 774.
   Google Scholar
• Walmsley S, Ruxrungtham K, Slim J, et al. Saquinavir/r (SQV/r) bid versus lopinavir/r (LPV/r) bid plus emtricit-abine/tenofovir (FTC/TDF) qd as initial therapy in HIV-1-infected patients: the Gemini Study. Presented at: the 11th European AIDS Conference (EACS); October 2007; Madrid, Spain. Presentation PS1/4.
   Google Scholar
• Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. AIDS. 2008;22:1389–1397.
   PubMed Web of Science ®Google Scholar
• Eron J, Jr., Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferior-ity trial. Lancet. 2006;368:476–482.
   PubMed Web of Science ®Google Scholar
• Smith KY, Weinberg WG, Dejesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infec-tion: 48-week results of ALERT. AIDS Res Ther 2008;5:5.
   PubMedGoogle Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritonavir, each in combi-nation with tenofovir and emtricitabine in ARV-naïve HIV-1-infected subjects: the CASTLE Study, 48-week results. Presented at: the 15th Conference on Retroviruses and Opportunistic Infections (CR01); February 2008; Boston, MA, USA. Presentation 37.
   Google Scholar
• Cooper D, Zajdenverg R, Ruxrungtham K, et al. Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naIve patients: results of BI 1182.33. Presented at: the 8th Inter-national Congress on Drug Therapy in HIV Infection; November 2006; Glasgow, UK. Abstract PL13.4.
   Google Scholar
• Gathe JC, Jr., Lye P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /rito-navir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS. 2004;18:1529–1537.
   PubMed Web of Science ®Google Scholar
• Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninfe-rior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006;43:153–160.
   PubMed Web of Science ®Google Scholar
• Gathe J, daSilva BA, Loutfy M, et al. Study M05-730 primary efficacy results at week 48: phase 3, random-ized, open-label study of lopinavir/ritonavir (LPV/r) tablets once-daily (qd) versus twice-daily (bid), co-administered with tenofovir DF (TDF) plus emtricitabine (FTC) in antiret-roviral-näive (ARV) HIV-1 infected subjects. Presented at: the 15th Conference on Retroviruses and Opportunistic Infections (CR01); February 2008; Boston, MA, USA. Abstract 775.
   Google Scholar
• Hicks C, DeJesus E, Wohl D, et al. Once-daily fosamprena-vir (FPV) boosted with either 100 mg or 200 mg of ritonavir (r) and combined with abacavir (ABC)/lamivudine (3TC): 48-week safety and efficacy results from COL100758. Presented at: the 11th European AIDS Conference (EACS); October 2007; Madrid, Spain. Abstract P5.7/01.
   Google Scholar
• Elion R, DeJesus E, Sension M, et al. Once-daily abacavir/ lamivudine and ritonavir-boosted atazanavir for the treat-ment of HIV-1 infection in antiretroviral-naive patients: a 48-week pilot study. HIV Clin Trials. 2008;9:152–163.
   PubMed Web of Science ®Google Scholar
• Simpson KN, Rajagopalan R, Dietz B. Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regi-mens in the CASTLE study. Adv Ther 2009;26: 185–193.
   PubMed Web of Science ®Google Scholar
• Basu RP, Grimes RM, Helmy AF. Cost to achieve an undetectable viral load using recommended antiretroviral regimens. HIV Clin Trials. 2006;7:309–318.
   PubMed Web of Science ®Google Scholar
• Sax PE, Losina E, Weinstein MC, et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. J Acquir Immune Defic Syndr. 2005;39:69–77.
   PubMed Web of Science ®Google Scholar
• Simpson KN, Jones WJ, Rajagopalan R, et al. Cost effec-tiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US. Clin Drug Invest. 2007;27:443–452.
   PubMed Web of Science ®Google Scholar
• Simpson KN, Luo MP, Chumney E, et al. Cost-effective-ness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infec-tion. HIV Clin Trials. 2004;5:294–304.
   PubMed Web of Science ®Google Scholar
• Simpson KN, Luo MP, Chumney EC, et al. Cost effective-ness of lopinavir/ritonavir compared with atazanavir in anti-retroviral-näive patients: modelling the combined effects of HIV and heart disease. Clin Drug Invest. 2007;27:67–74.
   PubMed Web of Science ®Google Scholar
• Simpson KN, Roberts G, Hicks CB, et al. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States. HIV Clin Trials. 2008;9:225–237.
   PubMed Web of Science ®Google Scholar
• Hill A, Sawyer W. Effects of nucleoside reverse tran-scriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. HIV Med. 2009;10:527–535.
   PubMed Web of Science ®Google Scholar
• Institute for Quality and Efficiency in Health Care. Methods for assessment of the relation of benefits to costs in the German statutory health care system. Version 1.1. September 10, 2008. Available at: http://www.igwig.de/index.805.en.html. Accessed April 9, 2009.
   Google Scholar
• Lee TA, Divers CH, Leibman CW. Evaluating the efficiency of treatment in the allergic rhinitis market. J Manag Care Pharm. 2004;10:S3–8.
   PubMedGoogle Scholar
• Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract. 2007;61:1979–1988.
   PubMed Web of Science ®Google Scholar
• Annemans L, Hill A, Smets E, et al. Cost-effectiveness of current treatment options in treatment-resistant HIV/AIDS patients in the German setting. Presented at: the 12th European AIDS Conference; November 2009; Cologne, Germany. Poster PE19.5/5.
   Google Scholar
• Red Book(FM) for W/ndows® [computer program]. Version 61127, Volume 53. Montvale, NJ: Thomson PDR; 2009.
   Google Scholar
• AIDS Drug Assistance Program (ADAP). February 4, 2004. Available at: http://www.natap.org/2004/HIV/020604_03.htm. Accessed April 9, 2009.
   Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopi-navir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646–655.
   PubMed Web of Science ®Google Scholar
• Boyle BA, Jayaweera D, Witt MD, et al. Randomization to once-daily stavudine extended release/lamivudine/ efavirenz versus a more frequent regimen improves adher-ence while maintaining viral suppression. HIV Clin Trials. 2008;9:164–176.
   PubMed Web of Science ®Google Scholar
• Viciana P, Rubio R, Ribera E, et al. Longitudinal study on adherence, treatment satisfaction, and effectiveness of once-daily versus twice-daily antiretroviral therapy in a Spanish cohort of HIV-infected patients (CUVA study). Enferm Infecc Microbiol Cl/n. 2008;26:127–134.
   PubMed Web of Science ®Google Scholar
• Hill A, Sawyer W, Gazzard B. Effects of nucleoside ana-logues versus ritonavir boosted protease inhibitors on lipid levels-analysis of 12 clinical trials in 4231 antiret-roviral naïve patients. Presented at: the XVII World AIDS Conference; August 2008; Mexico City, Mexico. Abstract THPE0167.
   Google Scholar